Local independent pharmacy models program after NCPA’s Dispose My Meds
ALEXANDRIA, Va. — A group representing the nation’s independent pharmacies praised a local drug store’s participation in a drug take-back program.
The National Community Pharmacists Association lauded the Great Peconic Take Back event, held Wednesday, which served the eastern Suffolk area of New York. Led by Bob Grisnik of Southrifty Drug, located in Southampton, N.Y., the free service allowed anyone wishing to safely dispose of his or her expired or otherwise unwanted prescription and over-the-counter medications to bring the medications to any of the 15 participating pharmacies of the newly formed Peconic Independent Pharmacy Association.
The program is based on the NCPA’s Dispose My Meds program, which addresses drug diversion and environmental contamination.
“It’s exciting to see community pharmacies working together to meet the growing patient demand for a safe and environmentally friendly way to discard unused medications. Programs like this should be voluntary, but I hope many pharmacies seize the opportunity to create their own programs to meet the needs of their patients,” said Robert Greenwood, NCPA president.
Takeda launches GetToKnowGERD.com
NEW YORK — Drug maker Takeda Pharmaceuticals is launching a campaign to raise awareness of gastroesophageal reflux disease, the company said Tuesday.
Takeda created the website GetToKnowGERD.com to coincide with GERD Awareness Week, which takes place from Nov. 21 to 27. The company also is using the occasion to promote the GERD drug Dexilant (dexlansoprazole).
GERD is an often chronic condition characterized by frequent heartburn that affects nearly 19 million Americans, but according to an Omnibus telephone poll of 1,000 U.S. adults conducted in October, around 80% of people are not aware of how common it is.
Labopharm reviewing notification of Actavis’ approval application for generic Oletpro
LAVAL, Quebec — Generic drug maker Actavis has filed for approval of a generic version of an antidepressant made by Canada’s Labopharm, Labopharm said.
The drug maker said it received a notification stating that Actavis had applied to the Food and Drug Administration for approval of a generic version of Oletpro (trazodone hydrochloride) extended-release tablets in the 150-mg and 300-mg strengths.
Actavis’ application contained a Paragraph IV certification, a legal challenge to a Labopharm patent covering the drug, which expires in June 2020. The market exclusivity period, which prevents the FDA from approving Actavis’ version, expires in February 2013.
Labopharm said it was reviewing the letter to determine what steps to take, though under the Hatch-Waxman Act of 1984, it is allowed to file a lawsuit against Actavis to prevent the latter from marketing its generic version of the drug.